Case report of a 49-year-old woman who developed new-onset type 1 diabetes shortly after initiating Wegovy (semaglutide) prescribed via an online clinic without prior metabolic screening. GAD65 antibody positivity and low C-peptide confirmed T1DM. Highlights the risk of prescribing semaglutide through digital channels without in-person biochemical screening—where latent autoimmune diabetes or T1DM could be unmasked by GLP-1 RA-induced appetite reduction, and rapid weight loss signals early-onset diabetes rather than expected therapeutic response.
Hasse, Laura; Wærling, Rosa Dam; Hansen, Baiba Hedegaard